Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
Omega Therapeutics, Inc. (OMGA)
Company Research
Source: GlobeNewswire
Programmable epigenomic mRNA candidates enabled durable and robust upregulation of gene expression across a diverse set of gene types and regulatory mechanismsAdditional OMEGA platform capabilities demonstrated, including reversible downregulation and multiplexed upregulation of gene expression CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the presentation of new preclinical data demonstrating durable and tunable bidirectional regulation of gene expression in cellular models at the pre-transcriptional level at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, taking place in Baltimore, Maryland, May 7 – 11. “These exciting new data underscore the versatile capabilities and power of our OMEGA platform,” said Thomas McCauley, Ph.D., Chief Scientific Officer of Omega
Show less
Read more
Impact Snapshot
Event Time:
OMGA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OMGA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OMGA alerts
High impacting Omega Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
OMGA
News
- Omega Therapeutics, Inc. (NASDAQ: OMGA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- UPDATE 1-Novo Nordisk ties up with Metaphore to develop new obesity drugs [Yahoo! Finance]Yahoo! Finance
- Omega Therapeutics, Inc. (NASDAQ: OMGA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.MarketBeat
- Omega Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line [Yahoo! Finance]Yahoo! Finance
- Omega Therapeutics, Inc. (NASDAQ: OMGA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $12.00 price target on the stock.MarketBeat
OMGA
Earnings
- 5/6/24 - Beat
OMGA
Sec Filings
- 5/6/24 - Form 10-Q
- 5/6/24 - Form 8-K
- 4/29/24 - Form DEFA14A
- OMGA's page on the SEC website